
United States · Nonprofit
A 501(c)(4) nonprofit focused on creating political power for the longevity industry to advance legislation that promotes accessible healthy lifespan.
A global non-profit organization that funds research and early-stage companies to extend healthy human lifespan.
A major nonprofit supporting aging research, notably managing the TAME (Targeting Aging with Metformin) Trial.

National Institute on Aging (NIA)
United States · Government Agency
A division of the U.S. NIH dedicated to aging research.
United Kingdom · Nonprofit
A think tank focused on the impact of longevity on society, producing reports on intergenerational fairness and inequality.
A Swiss foundation funding research to extend human healthspan, with a stated goal of making longevity care accessible.
Hosts the Global Future Council on Healthy Ageing and Longevity, which addresses the socioeconomic implications of extended lifespans.
Organizes the XPRIZE Healthspan, a $101M competition to restore muscle, cognitive, and immune function in older adults.
United States · University
A university center focused on the social and health inequalities of aging.
Singapore · Nonprofit
A professional medical society establishing clinical guidelines for longevity medicine to ensure safe and standardized application.
Longevity equity and access refers to the ethical challenge of ensuring that life-extending and healthspan-extending technologies are available equitably across society, avoiding a scenario where society becomes stratified into 'extended-life elites' who can afford longevity therapies and standard-lifespan populations who cannot, which could exacerbate existing inequalities and create new forms of social division. Ensuring equitable access to life-extending technologies is a major societal challenge that requires addressing questions about cost, distribution, healthcare systems, and the fundamental right to extended healthy life. This challenge involves balancing innovation incentives, healthcare economics, and social justice considerations. Policymakers, healthcare systems, and society are grappling with these questions.
This innovation addresses the risk that longevity technologies could create or exacerbate social inequalities, where only the wealthy could afford life-extending treatments, potentially creating permanent class divisions based on lifespan. By developing frameworks for equitable access, societies can ensure that longevity benefits are shared broadly. The challenge requires addressing healthcare economics, innovation incentives, and social values.
The technology is important for ensuring that longevity advances benefit all of society, not just the wealthy. As longevity therapies become available, equitable access becomes increasingly important. However, achieving equitable access while maintaining innovation incentives, managing costs, and addressing healthcare system capacity remains challenging. The technology represents an important area of policy and ethics, but requires difficult trade-offs and value judgments. Success could ensure that longevity benefits are shared equitably, but achieving this will require addressing fundamental questions about healthcare, economics, and social values. The challenge of longevity equity will become increasingly important as effective longevity therapies emerge.